{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-014402","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.123931+00:00","generated_at":"2026-05-22T16:05:02.400700+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"TG Therapeutics Q1 BRIUMVI sales $119.7M (+137% YoY); raises FY revenue guidance","bullets":["Q1 2025 BRIUMVI U.S. net revenue $119.7M vs $50.5M YoY, up ~137%.","Net income $5.1M vs net loss $10.7M in Q1 2024; GAAP improvement.","Raises FY2025 BRIUMVI U.S. net revenue target to ~$560M (prior $525M).","Raises FY2025 total global revenue target to ~$575M (prior $540M).","Q2 2025 BRIUMVI U.S. net revenue target set at $135M."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-014402","json":"https://secwatch.observer/filing/0001437749-25-014402.json","markdown":"https://secwatch.observer/filing/0001437749-25-014402.md","text":"https://secwatch.observer/filing/0001437749-25-014402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/0001437749-25-014402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925014402/tgtx20250502_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T16:05:02.400700+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}